title: Isolated lung perfusion for pulmonary metastases, a review and work in progress.
abstract: Pulmonary metastasectomy is a widely accepted treatment for many patients with pulmonary metastases from various solid tumors. Nevertheless, 5-year survival is disappointing, with rates of 25-40%, and many patients develop recurrences. Isolated lung perfusion (ILuP) is a promising new technique to deliver high-dose chemotherapy to the lungs, while minimising systemic toxicities. This procedure is technically safe and feasible; however, clinical value and efficacy remain unclear. The aim of this paper is to give a review of literature on ILuP in humans, and to describe the development of the perfusion procedure in our institute.
authors.affiliation: Department of Pulmonary Medicine, St Antonius Hospital, Nieuwegein, The Netherlands. marcogrootenboers@hetnet.nl
authors.forename: Marco J J H
authors.initials: MJ
authors.lastname: Grootenboers
authors.forename: Jos
authors.initials: J
authors.lastname: Heeren
authors.forename: Bart P
authors.initials: BP
authors.lastname: van Putte
authors.forename: Jeroen M H
authors.initials: JM
authors.lastname: Hendriks
authors.forename: Wim J
authors.initials: WJ
authors.lastname: van Boven
authors.forename: Paul E Y
authors.initials: PE
authors.lastname: Van Schil
authors.forename: Franz M N H
authors.initials: FM
authors.lastname: Schramel
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001804:Blood Transfusion, Autologous; D002277:Carcinoma / Q000188:drug therapy / Q000556:secondary / Q000628:therapy; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000295:instrumentation / Q000379:methods*; D017321:Clinical Trials, Phase I as Topic; D003131:Combined Modality Therapy; D004354:Drug Screening Assays, Antitumor; D004618:Embolism, Air / Q000517:prevention & control; D004867:Equipment Design; D015199:Extracorporeal Membrane Oxygenation / Q000295:instrumentation; D005240:Feasibility Studies; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives; D006979:Hyperthermia, Induced; D007431:Intraoperative Complications / Q000517:prevention & control; D007552:Isotonic Solutions; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000628:therapy; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use; D010865:Pilot Projects; D012212:Rheology; D000077325:Ringer's Lactate; D012509:Sarcoma / Q000188:drug therapy / Q000556:secondary / Q000628:therapy; D012996:Solutions; D013696:Temperature; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; C485123:HES 130-0.4; D006895:Hydroxyethyl Starch Derivatives; D007552:Isotonic Solutions; D000077325:Ringer's Lactate; D012996:Solutions; D008558:Melphalan